Nevertheless, we were able to identify several classes of small molecule inhibitor that selectively target cells expressing MYCN protein, and as proof-of-principle we characterized one class of compound that demonstrated considerable efficacy in two independent pre-clinical models of MYCN-driven neuroblastoma. Here, MYCN is linked to neuroblastoma.